Sign in or create an account to add this stock to your watchlist.
About Akorn (NASDAQ:AKRX)
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio1.01
Current Ratio4.64
Quick Ratio3.37
Price-To-Earnings
Trailing P/E Ratio8.74
Forward P/E Ratio26.55
P/E Growth1.15
Sales & Book Value
Annual Sales$841.04 million
Price / Sales2.10
Cash Flow$0.5264 per share
Price / Cash26.73
Book Value$6.47 per share
Price / Book2.17
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,550,000.00
Net Margins-12.22%
Return on Equity-9.63%
Return on Assets-4.20%
Miscellaneous
Employees2,308
Outstanding Shares125,260,000
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn (NASDAQ:AKRX) announced its earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.03. The company earned $280.70 million during the quarter, compared to analysts' expectations of $272.99 million. Akorn had a negative net margin of 12.22% and a negative return on equity of 9.63%. The business's revenue was up 27.1% on a year-over-year basis. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 equities research analysts have issued 1-year price objectives for Akorn's stock. Their predictions range from $14.00 to $34.00. On average, they expect Akorn's stock price to reach $28.20 in the next twelve months. View Analyst Ratings for Akorn.
Are investors shorting Akorn?
Akorn saw a drop in short interest in May. As of May 15th, there was short interest totalling 10,488,176 shares, a drop of 16.6% from the April 30th total of 12,582,108 shares. Based on an average trading volume of 4,564,948 shares, the days-to-cover ratio is presently 2.3 days. Currently, 11.3% of the company's shares are sold short.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Hutchison China MediTech (HCM), Blueprint Medicines (BPMC) and Ultragenyx Pharmaceutical (RARE).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Has Akorn been receiving favorable news coverage?
Press coverage about AKRX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akorn earned a news sentiment score of 0.10 on Accern's scale. They also gave headlines about the company an impact score of 47.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Akorn's major shareholders?
Akorn's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.56%), Melqart Asset Management UK Ltd (1.11%), Dimensional Fund Advisors LP (0.93%), Gabelli Funds LLC (0.59%), Allianz Asset Management GmbH (0.56%) and Allianz Asset Management GmbH (0.56%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, John N Kapoor, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.
Which institutional investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including OMERS ADMINISTRATION Corp, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Cheyne Capital Management UK LLP, State of Wisconsin Investment Board, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC. and Guggenheim Capital LLC. Company insiders that have sold Akorn company stock in the last year include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Insider Buying and Selling for Akorn.
Which institutional investors are buying Akorn stock?
AKRX stock was purchased by a variety of institutional investors in the last quarter, including Melqart Asset Management UK Ltd, Nexthera Capital LP, BlackRock Inc., Elo Mutual Pension Insurance Co, Ancora Advisors LLC, Alpine Associates Management Inc., PointState Capital LP and UBS Group AG. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $14.07.
How big of a company is Akorn?
Akorn has a market capitalization of $1.76 billion and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe.
How can I contact Akorn?
Akorn's mailing address is 11925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akorn (NASDAQ:AKRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Akorn in the last 12 months. Their average twelve-month price target is $28.20, suggesting that the stock has a possible upside of 100.43%. The high price target for AKRX is $34.00 and the low price target for AKRX is $14.00. There are currently 6 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.20 | $28.20 | $32.20 | $30.1429 |
| Price Target Upside: | 100.43% upside | 115.60% upside | 2.61% upside | 7.31% downside |
Akorn (NASDAQ:AKRX) Consensus Price Target History
Akorn (NASDAQ:AKRX) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Akorn (NASDAQ:AKRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akorn (NASDAQ AKRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.20%
Institutional Ownership Percentage: 65.62%
Akorn (NASDAQ AKRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/25/2018 | John N. Kapoor | Major Shareholder | Sell | 13,629 | $32.67 | $445,259.43 | |  |
| 11/21/2017 | Brian Tambi | Director | Sell | 15,100 | $33.35 | $503,585.00 | | |
| 8/4/2017 | Brian Tambi | Director | Sell | 5,165 | $33.37 | $172,356.05 | | |
| 8/3/2017 | Bruce Kutinsky | COO | Sell | 40,000 | $33.46 | $1,338,400.00 | 317,480 | |
| 8/15/2016 | Kenneth Abramowitz | Director | Sell | 2,691 | $30.44 | $81,914.04 | 20,786 | |
| 6/14/2016 | Joseph Bonaccorsi | SVP | Sell | 6,500 | $29.84 | $193,960.00 | 449,112 | |
| 6/10/2016 | Kenneth Abramowitz | Director | Sell | 14,675 | $30.16 | $442,598.00 | 33,185 | |
| 6/9/2016 | Bruce Kutinsky | COO | Sell | 142,000 | $31.12 | $4,419,040.00 | 58,695 | |
| 6/7/2016 | Ronald M Johnson | Director | Sell | 7,542 | $31.49 | $237,497.58 | 111,807 | |
| 6/6/2016 | Kenneth Abramowitz | Director | Sell | 10,900 | $31.37 | $341,933.00 | 16,985 | |
| 6/3/2016 | Joseph Bonaccorsi | SVP | Sell | 90,250 | $31.23 | $2,818,507.50 | 470,862 | |
| 6/2/2016 | Alan D Weinstein | Director | Sell | 50,000 | $30.93 | $1,546,500.00 | 83,857 | |
| 4/21/2015 | Mark M Silverberg | VP | Sell | 29,000 | $55.00 | $1,595,000.00 | | |
| 3/10/2015 | John N Kapoor | Director | Buy | 19,000 | $44.26 | $840,940.00 | | |
| 3/3/2015 | Rajat Rai | CEO | Buy | 5,000 | $47.70 | $238,500.00 | | |
| 2/18/2015 | Joseph Bonaccorsi | Insider | Sell | 40,827 | $47.33 | $1,932,341.91 | | |
| 2/10/2015 | Ronald M Johnson | Director | Sell | 17,173 | $46.44 | $797,514.12 | | |
| 1/26/2015 | Rajat Rai | CEO | Sell | 873,985 | $41.89 | $36,611,231.65 | | |
| 1/12/2015 | Mark M Silverberg | VP | Sell | 38,602 | $41.00 | $1,582,682.00 | | |
| 1/9/2015 | Ronald M Johnson | Director | Sell | 17,173 | $40.46 | $694,819.58 | | |
| 1/2/2015 | Ronald M Johnson | Director | Sell | 14,300 | $36.12 | $516,516.00 | | |
| 1/2/2015 | Timothy A Dick | CFO | Sell | 30,150 | $36.03 | $1,086,304.50 | | |
| 12/15/2014 | Brian Tambi | Director | Sell | 1,200 | $41.86 | $50,232.00 | | |
| 12/12/2014 | Adrienne L Graves | Director | Sell | 9,557 | $41.09 | $392,697.13 | | |
| 12/11/2014 | John N Kapoor | Director | Sell | 50,000 | $41.19 | $2,059,500.00 | | |
| 12/9/2014 | John R Sabat | VP | Sell | 43,173 | $40.53 | $1,749,801.69 | | |
| 12/1/2014 | Timothy A Dick | CFO | Sell | 30,875 | $39.23 | $1,211,226.25 | | |
| 11/3/2014 | Timothy A Dick | CFO | Sell | 122,222 | $44.08 | $5,387,545.76 | | |
| 10/1/2014 | Timothy A Dick | CFO | Sell | 122,222 | $35.24 | $4,307,103.28 | | |
| 9/12/2014 | Brian Tambi | Director | Sell | 13,800 | $38.00 | $524,400.00 | | |
| 9/11/2014 | Joseph Bonaccorsi | Insider | Sell | 116,800 | $37.89 | $4,425,552.00 | | |
| 9/8/2014 | Kenneth Abramowitz | Director | Sell | 4,500 | $36.54 | $164,430.00 | | |
| 9/8/2014 | Rajat Rai | CEO | Sell | 147,000 | $36.78 | $5,406,660.00 | | |
| 9/8/2014 | Timothy A Dick | CFO | Sell | 45,000 | $37.61 | $1,692,450.00 | | |
| 9/4/2014 | Alan D Weinstein | Director | Sell | 5,000 | $38.49 | $192,450.00 | | |
| 8/26/2014 | John N Kapoor | Director | Sell | 50,000 | $38.99 | $1,949,500.00 | | |
| 8/7/2014 | Rajat Rai | CEO | Sell | 903,659 | $33.62 | $30,381,015.58 | | |
| 6/13/2014 | Brian Tambi | Director | Buy | 1,000 | $27.62 | $27,620.00 | | |
| 5/16/2014 | Rajat Rai | CEO | Buy | 5,000 | $26.76 | $133,800.00 | 31,271 | |
| 5/14/2014 | Kenneth Abramowitz | Director | Sell | 2,557 | $26.79 | $68,502.03 | 4,300 | |
| 12/9/2013 | Alan Weinstein | Director | Sell | 20,000 | $25.52 | $510,400.00 | 53,857 | |
| 12/3/2013 | Kenneth Abramowitz | Director | Sell | 5,000 | $25.35 | $126,750.00 | 21,057 | |
| 12/12/2012 | Alan D Weinstein | Director | Buy | 30,500 | $13.67 | $416,935.00 | | |
(Data available from 1/1/2013 forward)
Akorn (NASDAQ AKRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Akorn (AKRX) Short Interest Update
www.americanbankingnews.com - May 27 at 2:28 AM |
 | RBC Has an Unchanged View on Akorn (AKRX) Merger Following Expert Call
www.streetinsider.com - May 24 at 9:21 AM |
| RBC Still Sees a Path to Closing of Akorn (AKRX) Merger
www.streetinsider.com - May 23 at 4:42 PM |
| Brokerages Anticipate Akorn (AKRX) Will Post Quarterly Sales of $185.75 Million
www.americanbankingnews.com - May 23 at 4:12 AM |
| $0.15 Earnings Per Share Expected for Akorn (AKRX) This Quarter
www.americanbankingnews.com - May 21 at 7:44 AM |
 | Fresenius CEO defends canceled Akorn deal
www.reuters.com - May 18 at 9:59 AM |
| UPDATE 1-Fresenius CEO defends cancelled Akorn deal
www.reuters.com - May 18 at 9:59 AM |
| Akorn (AKRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 14 at 1:30 AM |
 | Bull bet on this under the radar pharma stock
www.cnbc.com - May 12 at 9:59 AM |
| Bullish Options Activity in Akorn (AKRX) Following 22% Sell-Off Over Last 2 Days Since Earnings Release -Susquehanna
www.streetinsider.com - May 11 at 4:38 PM |
| Akorn (AKRX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 11 at 11:13 AM |
| Akorn (AKRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 11 at 3:06 AM |
| Akorn (AKRX) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - May 8 at 1:41 PM |
| Akorn (AKRX) Recently Received ANDA Approval Out of Decatur Facility - RBC
www.streetinsider.com - May 7 at 4:44 PM |
 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - May 7 at 4:44 PM |
| FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
finance.yahoo.com - May 7 at 4:44 PM |
| DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX
finance.yahoo.com - May 7 at 4:44 PM |
| Akorn (AKRX) Expected to Announce Quarterly Sales of $185.75 Million
www.americanbankingnews.com - May 5 at 2:10 AM |
| DEADLINE MONDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)
finance.yahoo.com - May 4 at 4:31 PM |
| Akorn (AKRX) Expected to Post Earnings of $0.15 Per Share
www.americanbankingnews.com - May 3 at 11:26 PM |
| Akorn (AKRX) on Watch as FDA Posts Inspection Letter
www.streetinsider.com - May 3 at 4:31 PM |
| AKRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018
finance.yahoo.com - May 3 at 4:31 PM |
| MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - May 3 at 4:31 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX
finance.yahoo.com - May 3 at 9:12 AM |
| UPDATE: Akorn (AKRX) Accused of Submitting Phony Data to FDA on Antibiotic Drug - Bloomberg
www.streetinsider.com - May 2 at 4:37 PM |
| Fresenius alleges "blatant fraud" at abandoned target Akorn
www.reuters.com - May 2 at 4:37 PM |
| Fresenius alleges 'blatant fraud' at US drugmaker Akorn
www.reuters.com - May 2 at 4:37 PM |
 | Reviewing The Akorn-Fresenius Merger Fallout
seekingalpha.com - May 2 at 9:19 AM |
| 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - May 2 at 9:19 AM |
| Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action – AKRX
finance.yahoo.com - May 1 at 4:30 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
finance.yahoo.com - April 30 at 4:32 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX
finance.yahoo.com - April 30 at 4:32 PM |
| Deutsche Bank Reiterates Hold Rating for Akorn (AKRX)
www.americanbankingnews.com - April 30 at 11:08 AM |
| Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up
seekingalpha.com - April 30 at 9:30 AM |
 | Fresenius Accused of Nixing Akorn Deal Over Buyer's Remorse
www.bloomberg.com - April 27 at 4:33 PM |
| Akorn (AKRX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 27 at 12:13 PM |
| Akorn Forecasted to Post FY2018 Earnings of $0.51 Per Share (AKRX)
www.americanbankingnews.com - April 27 at 9:20 AM |
| DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 26 at 4:33 PM |
| Akorn Target of Unusually Large Options Trading (AKRX)
www.americanbankingnews.com - April 25 at 8:12 AM |
 | AKORN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class ...
globenewswire.com - April 24 at 4:46 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 – AKRX
finance.yahoo.com - April 24 at 4:46 PM |
| Fresenius Abandons $4.3 Billion Takeover Bid
www.bloomberg.com - April 23 at 4:31 PM |
 | Is the Options Market Predicting a Spike in Akorn (AKRX) Stock? April 23, 2018
www.zacks.com - April 23 at 4:31 PM |
| 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 23 at 4:31 PM |
| Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%
finance.yahoo.com - April 23 at 4:31 PM |
| Akorn Shares Crash After Fresenius Walks Away From Merger Deal
finance.yahoo.com - April 23 at 4:31 PM |
| Piper Jaffray Reiterates Hold Rating for Akorn (AKRX)
www.americanbankingnews.com - April 23 at 9:48 AM |
| Craig Hallum Reiterates "Hold" Rating for Akorn (AKRX)
www.americanbankingnews.com - April 23 at 9:18 AM |
| BRIEF-Akorn Asks Delaware Court To Require Fresenius Kabi To Fulfill Its Obligations Under Merger Agreement
www.reuters.com - April 23 at 9:04 AM |
| Fresenius shares gain after it ditches Akorn takeover
finance.yahoo.com - April 23 at 9:04 AM |
Akorn (NASDAQ:AKRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akorn (NASDAQ:AKRX) Income Statement, Balance Sheet and Cash Flow Statement
Akorn (NASDAQ AKRX) Stock Chart for Sunday, May, 27, 2018
Loading chart…
